Sources of Heterogeneity in the Efficiency of Indian Pharmaceutical Firms
Performance of firms may differ widely even if they use the same set of inputs and identical production technology. Although the neo-classical theory of firm does not underline such differences, a vast body of recent literature provides evidence of firm heterogeneity in a narrowly defined industry (Caves, 1998; Bartelsman and Doms, 2000; Tybout, 200o; Ahn, 2001) . The studies underline the importance of firm specific intrinsic factors, technical and managerial skills for such persistent differences. Theoretical models of firm dynamics have formalized this concept of firm heterogeneity and discussed its importance on the productive performance at the firm level (see Ahn, 2001) .
In this paper, we examine the importance of firm specific factors for persistent performance differences for the Indian pharmaceutical firms, which are undergoing through a phase of transition due to policy changes.
The Indian pharmaceutical industry has the distinction of being the leader in the production of generic drugs sought eagerly throughout the world. Starting from a barebones existence under total dominance by multinational companies, the industry has emerged as a major player in the international stage as the 4 th largest manufacturer of pharmaceutical drugs in the world and widely respected for its high quality low cost generic drugs. Over the first two decades since independence, the 50s and the 60s, the domestic market in India was almost entirely import dependent and drug prices were among the highest in the world. Virtually all of the pharmaceutical drug patents in India were held by multinational companies. In order to ensure self sufficiency in the supply of basic drugs and to end foreign domination of the industry in general, the Government of India introduced a number of important regulatory changes facilitating entry by a large number of small firms. What contributed most to the phenomenal growth of the domestic industry was the Patents Act of 1970 which replaced product patents by process patents.
Process patent allows an indigenous firm to manufacture through reverse engineering a generic substitute of an existing patented pharmaceutical product without paying a licensing fee so long as the production process for the generic substitute differed from the one used by the patent owner. Further, the Drug Price Control Order, also introduced in 1970, imposed rigid price control on most of the drugs in the market with explicitly stipulated "maximum retail price" for the product. While these policies fostered competition, the industry remained highly regulated through import restrictions, high tariff rates, and ceiling on foreign equity participation.
In many ways, the experience of the Indian pharmaceuticals industry is a "poster child"
for the infant industry argument for protective trade policies. It effectively nurtured the domestic industry into a sustainable stage of development. The consumers benefited from greater access to basic drugs at reasonable prices. The only drawback was that it permitted a large number of smaller firms, the so called unorganized sector of the industry to operate profitably in a highly knowledge-based industry by essentially copying the processes developed by others without having to develop their own Research and Development (R&D) capabilities.
The era of protected development virtually ended with the enactment of the Amended patents Act in 2005 reintroducing product patents in place of process patents. Under the provisions of this amended Act, it was no longer legal to manufacture generic substitutes for products patented in 1995 or later. Also, as a part of the liberalization policy following the economic reforms, restrictions on importation of bulk drugs were removed and the scope of price control was limited to fewer drugs with the expectation that the liberalized market environment would allow firms to function freely in response to market forces by entering into technological collaboration with the foreign firms, exploiting economies of scale due to market expansion, and introducing new products and processes. This in turn would enable firms to achieve higher efficiency and productivity.
However, all firms may not benefit equally from a competitive environment in a knowledge-intensive sector like pharmaceuticals, where firms differ with respect to their access to technology and state-of-knowledge. In the Indian pharmaceutical industry, firms flourished by imitating the patented products of the foreign firms under the process patent regime of 1970. Also a number of protective policies and assured market from the government of India (see, Pradhan and Sahu, 2009 ) supported the growth of large number of small firms in this sector. Most of these firms invested little in Research and Development (R&D) and undertook few initiatives to upgrade their production base. On the other hand, the imposition of product patent, increased liberalization, global exposure and the bio-technological revolution in the drug discovery and manufacturing process have led to rapid technological change (see Mazumdar and Rajeev, 2009 ) and opened up new production opportunities that these firms might have failed to appropriate.
Consequently, the process of liberalization may create gainers and losers and performance differential may arise between firms. In this regard, analyzing efficiency of the firms is one of the most appropriate methods to examine the performance differential.
This paper is primarily devoted to such an investigation.
Numerous papers have appeared both in the business press and in academic journals focusing on the opportunities as well as the threats faced by the Indian pharmaceutical firms as the industry make the transition from one patent regime to the other. Joshi (2003) analysis that the market perception about them is that they have been able to withstand the change successfully. The authors notice in passing that over the year raw materials cost as percentage of sales has gone down which in turn has helped raise profitability. Mishra and Chandra (2010) used data from 52 companies in a panel data regression for the years 2001-8 to examine the importance of mergers and acquisitions (M&A) in explaining the profitability of firms in the Indian pharmaceuticals industry. They concluded that there is no evidence of any significant impact of M&A in the long run.
Further, they conclude that in-house R&D activity is not a significant determinant of profitability either. In view of the fact that technological capability built through R&D as well as scale economies achieved through M&A are both perceived to be important in the product patent regime, these conclusions are somewhat surprising.
While financial efficiency is the ultimate goal of a company, market perception about a manufacturing firm is ultimately driven by its operational or productive efficiency. A firm cannot remain profitable unless it succeeds in eliminating surplus (or unutilized) inputs while at the same time achieving the potential output levels from the quantities of inputs used. In other words, it has to attain full technical efficiency. Few studies in the existing literature have examined the productive or technical efficiency of the pharmaceutical firms in India. Majumdar (1994) is one of the earliest studies that examined input-oriented efficiency of a small number of pharmaceutical companies over the years 1987 through 1990 using the nonparametric method of Data Envelopment Analysis (DEA). He concluded that, in general, public sector firms performed worse than the private sector firms. His empirical findings are of no particular relevance in the present context because (a) the sample size is extremely small and (b) the data relate to a period that is well before the change in the Patents act. In this analysis, we simultaneously measure output and input efficiencies for Indian pharmaceutical firms. The Pareto-Koopmans model that we use to compute the efficiency reflects all potential increase in outputs 3 alongside all potential reduction in inputs. We provide a decomposition of this overall efficiency into two separate factors reflecting the output and input efficiencies of a firm.
While the DEA efficiency score of a firm provides an assessment of its performance, a statistical analysis of the relationship between the measured efficiency scores and a number of relevant characteristics of a firm can identify how efficiency varies with changes in these attributes. This can be quite useful for policy. For example, if it is found that investment in R&D does enhance efficiency, government policy fostering such investment would be recommended.
The rest of the paper unfolds methodology applied in this paper. Section 2 explains briefly the nonparametric DEA methodology and the non-radial models used in this paper. Section 3 describes the data and reports the DEA findings. Section 5 uses a second-stage regression to identify the determinants of the efficiency scores of the individual firms. Section 6 is the conclusion.
The Nonparametric Methodology

The Technology and Technical Efficiency
Consider an industry producing bundles of m outputs y from bundles of n inputs x.
The production technology is defined by the production possibility set
The bundle (x 0 , y 0 ) is weakly efficient in its input-orientation if it is not possible to reduce all inputs simultaneously without reducing any output. That is,
That is all outputs cannot be increased simultaneously without increasing any input.
Note that input-oriented weak efficiency does not preclude reduction in one or more (though not all) inputs. Similarly, output-oriented weak efficiency is compatible with increase in one or more individual outputs. Thus, weak efficiency does not imply Pareto efficiency. Both input-and output-oriented weak efficiencies are essentially radial in nature because one considers radial contraction of the input bundle or a radial expansion of the output bundle. 
Thus, strong input-and output-efficiency are both necessary and are together sufficient for Pareto-Koopmans efficiency.
Data Envelopment Analysis
In order to calibrate any of the various technical efficiency measures considered above, we need to construct the production possibility set empirically from observed data. In parametric models, one starts with an explicit specification of the production technology in the form of a production function (in the single output case) or a transformation function (in the multiple output case) and uses appropriate statistical methods to obtain estimates of the parameters of the specified function from sample data. By contrast, in the nonparametric approach of Data Envelopment Analysis (DEA) one makes a number of fairly general assumptions about the underlying technology but specifies no explicit functional form. Introduced by Charnes, Cooper, and Rhodes (CCR) (1978) and further generalized by Banker, Charnes, and Cooper (BCC) (1984) , DEA allows one to construct the production possibility set empirically from observed data. Specifically, one makes the following assumptions:
Each input-output bundle (x j , y j ) (j = 1,2,…,N) actually observed in the sample is feasible.
(ii) The production possibility set T is convex.
(iii) Inputs are strongly disposable. That is, if T y and
Outputs are freely disposable. That is, if T y and y 1 ≤ y 0 , then
It can be easily verified that the free disposal convex hull of the observed input-output
is the smallest set satisfying assumptions (i)-(iv)
Radial Measures of Technical Efficiency
Following Banker, Charnes, and Cooper (1984) , the input-oriented radial technical efficiency of a firm with an observed input-output bundle (x 0 , y 0 ) under the variable returns to scale assumption is obtained as:
Similarly, the output-oriented radial technical efficiency under VRS is measured as ϕ λ
It is obvious that neither the input-nor the output-oriented radial measure of technical efficiency is affected by the presence (or magnitude) of slacks in any of the individual input or output constraints in (6) or (7).
Non-Radial Measures of Technical Efficiency
The problem of slacks in any optimal solution of a radial DEA model arises because we seek to expand all outputs or contract all inputs by the same proportion. In non-radial models, one allows the individual outputs to increase or the inputs to decrease at different rates. Färe and Lovell (1978) introduced the following input-oriented, nonradial measure of technical efficiency called the Russell measure:
When input slacks do exist at the optimal solution of a radial DEA model, the nonradial Russell measure in (8) falls below the conventional measure obtained from an input-oriented BCC model (6). Because the radial projection is always a feasible solution for (8), .
That is, the non-radial Russell measure of technical efficiency never exceeds the corresponding radial measure.
The analogous output-oriented non-radial VRS measure of technical efficiency is: 
While no input slacks can exist at the optimal solution of (8), presence of any output slack is not ruled out. Similarly, input slacks may remain at the optimal solution of (9).
Thus, non-radial technical efficiency (whether input-oriented or output-oriented) by itself does not ensure over all Pareto efficiency. 
Thus, 
We may, therefore, replace the objective function in (10) by (13) and solve (10) iteratively using the optimal solution from each iteration as the point of approximation for the next iteration until convergence. Once we obtain the optimal from this problem, we evaluate Apart from an overall measure, (14) also provides information about the potential for reducing individual inputs and increasing individual outputs Also a decomposition of (14) into the input-and output-oriented components can be obtained from (12).
The Empirical Analysis using DEA
The study conceptualized a 1-output, 4-input production technology. Output in the model is the value of total output ( ) defined as the total sales of firms plus the change in the stock of output measured in terms of the opening stock minus the closing stock in output. The inputs in the model are (i) labor (measured by the total wages and salaries paid, (ii) material inputs (measured by the total expenditure on raw materials), (iii) energy input (measured by the expenditure for power and fuel) and (iv) capital ( the book value for plant and machinery and building). In an inter-temporal analysis of efficiency, one needs to make explicit assumptions about the as done in the earlier literature (see Caves and Barton, 1990; Tybout et al, 1991; Aw et al, 2001; Pavcnik, 2002 and so on). This is useful particularly when firms produce differentiated products and /or face differentiated input market and also the product varieties differ across the firms. In a sense the efficiency measures computed in these research works including the current ones closely corresponds to indices of revenue per unit of input expenditure (see Katayama, Lu and Tybout, 2009 ).
5 The Prowess Data-Base provides firm level information from the year 1989 to the current year. However, data are consistently available only from the year 1991. Therefore the study period from 1991 to 2005 is considered in this paper. Also most of the policy changes for this sector are implemented between the year 1995 and 1998. 6 The figures has been arrived at by taking the ratio of the output manufacturing by the registered Indian pharmaceutical companies ( provided by the CMIE prowess data base) to the total value of output produced by the sector (provided by the Ministry for Chemical and Petro-Chemical).
In this and input-specific efficiency scores of the Indian pharma
(1) Efficiency analysis, we use sequential frontier. It is assumed that in any given year the inputoutput bundles from previous years remain feasible but no such assumption is made about observations from the subsequent years. This allows for an outward shift of the frontier and an enlarged production possibility set over the years but technological regress is ruled out. An outward shift of the frontier over time may be caused by a greater degree of involvement of firms in R&D, import of capital good and investments in modern plant and machinery.
In our empirical analysis the DEA model (10) above has been employed. Given the choice of inputs and output, specific efficiency scores are available for output and the four inputs: (i) raw material, (ii) power and fuel, (iii) labor, and (iv) capital. Table 1 reports the average output ceutical firms for each year. Ray, 2002; Mukherjee and Ray, 2004; Srivastava, 2001; Parameshwaran, 2001 , Siddharthan and Lal, 2004 . A steady decline in the mean output efficiency for the sector no doubt is an indication of the fact that difference between the output produced by the frontier firms and the firms that lie below the frontier are increasing over the years. It is interesting to speculate on the possible reasons for the observed efficient use of raw material and labor alongside inefficient use of power and fuel by the Indian pharmaceutical firms. Raw material easily fits the textbook d that can be easily adjusted with a change in the level of output. India has a welldeveloped chemical industry (see Kaul, 2007) , which provides the raw materials to the pharmaceutical industry. With good linkages with the raw-material industry, it is expected that the Indian firms will be able to use raw material as and when required in appropriate quantities efficiently. Input use efficiency is found to be quite high in respect of labor also. In the recent years most with liberalized labour laws, firms being able to hire and fire labor possibly accounts for the observed efficiency in respect of this particular input. that have undertaken initiative to conserve energy for the production process by replacing the old with the modern technology are the efficient ones. The rest of the firms still use technology that consumes more energy per unit of the output generated and thereby lead to energy wastage. It is noteworthy that the share of consumption of power and fuel has increased for the sector from about 4.5 % to about 8 % of the total cost of production from 1995 to 2005. However, for large firms the share of power and fuel consumption in the total expenditure has remained at around 2 %. For tiny, small and medium size firms the share of power and fuel consumption has increased by around 4 percent to 5 percent due to inefficient use of fuel. It is important to note here that in the small and medium size group a few firms that have replaced coal-based technology to diesel and gas to generate power display lower share of power and fuel consumption. As expected they are the efficient firms within this group.
On the whole, we observe that the average efficiency of the sector in its use of different factors of production is hig Cosmetic Act. Moreover, many firms have also upgraded their production system to comply with the standard set by the regulatory body of the developed countries to export their product there. Firms undertake such investment keeping in view the possible market expansion. Since, return from capital stock generally takes time to realize it may not be possible for a firm to realize fully the potential benefit of the capital stock at least in the short run.
analysi E and F in the diagram represent two inefficient firms. Firm E lies in the Increasing
Returns to Scale (IRS) zone of the production frontier and firm F lies in the Decreasing
Returns to Scale (DRS) zone. By construction, both th e sam level of input inefficiency as AB = CD; however, it is evident from the diagram that the output s. Thus, price of an output may be a determining factor for output efficiency of the firms. The price of an output depends on the underlying market structure and the demand for the product. If a firm uses its input comparatively efficiently but fails to get a fair price for its product due to low level of demand, it will show low level of output efficiency. The second reason is more compelling and could be due to the returns to scale (RTS) in production. When the underlying production technology exhibits 'economies of scale' in production, the output and the input inefficiencies of firms differ. Consider, for example, Figure 1 which depicts a production technology with returns to scale in production.
Fig1: Input and Output (In) Efficiency with VRS Technology
Y e firms hav e inefficiency for firm E (=BG) is much higher compared to firm F (=DH) that lies in the DRS zone of the production frontier. Thus compared to a firm that lie in the DRS zone, the magnitude of output inefficiency can be much higher for a firm in the IRS zone, even though they have same level of input inefficiency. As a large number of firms in our 
Firm Specific Factors and Firm Efficiency
In the non parametric approach for efficiency analysis using DEA, it is a common practice to estimate a regression model in the second stage explaining the variation in the measured efficiency scores on the basis of a set of explanatory variables (Ray 1991; Chilingerian and Sherman 2004; McCarty and Yaisawarng 1993; Duncombe et al Ray, 2004; and Ruggiero, 2004) . The approach to link the mathematically computed DEA efficiency scores with its determinants was first introduced and further developed by Ray (1988 Ray ( , 1991 . Since DEA efficiency scores lie naturally within the (0, 1] interval, use of a Tobit model 10 instead of the ordinary square regression has often been justified (see Ray 2004 among others). However, this ad hoc approach lacks a serious datagenerating process (DGP)( see Kennedy, 1998; Härdle and Simar, 1999 and so on for a detailed discussion on DGP ) that would conceptually link the non-parametric deterministic DEA efficiency score with the statistical two-stage regression analysis.
Responding to the need for developing a proper framework, Simar and Wilson (2007) defined a DGP that would make the second stage regression analysis sensible. Simar and Wilson (2007) Papke and Wooldridge (1996) in the context of fractional data; but he also notes that the OLS procedure would provide a reasonable approximation. Thus it is evident that there is no clear consensus in the profession about how the second stage analysis (following up on DEA) should be carried out 12 . In this paper, we opt for the simple OLS method because there is no compelling reason for performing the bootstrap.
An important objective of this paper is to explain the heterogonous performance of the Indian pharmaceutical firms and identify the firm specific intrinsic factors that explain such heterogeneity. This is achieved by carrying out a regression analysis for the logarithmic transformation of the output efficiency scores of firms 13 . The independent variables considered in our model are mainly firm specific attributes and can be broadly classified into three groups: (a) strategy variables, (b) structural variables, and (c) policy related variable.
Strategy Variables
A strategy is a plan of action designed to achieve a particular set of goals.
hether or not to invest in research and development is an important strategic decision W 11 The Monte-Carlo Stimulation carried out in the second stage indicate that the two stage method with DEA based efficiency in the first stage and OLS, maximum likelihood or even Tobit estimations, in the second stage performs far better than the parametric methods. Banker and Nataranjan (2008) paper assumes a form of Data Generating Process (DGP) that is much more flexible and less restrictive than the one assumed by Simar and Wilson(2007) that has also examined the impact of contextual variables on the efficiency of firms in a two-stage process. While Simar and Wilson(2007) paper argues that ML estimation of a truncated regression rather than the Tobit model is the preferred approach in the second stage; the Banker and Natarajan (2008) results are more robust and appropriate than the Simar and Wilson (2007) approach. 12 Recent, as yet unpublished, simulation studies by Banker and his coauthors have shown that the simple OLS procedure performs better than the Simar-Wilson bootstrap methods which are computationally overwhelming. 13 We have also tried to estimate a regression model each of the input as well as for the total input efficiency scores of the firms. Since the explanatory powers of the models were low, we concentrate here primarily on output efficiency scores. Intuitively also it makes more sense to consider only output efficiency scores in our regression model because we notice that on an average firms are input efficient. A suitable proxy for the R&D effort of a firm is its R&D intensity measured in terms of ratio of firm's expenditure on R&D to its value of sales. Firms successful in their R&D efforts can invent superior processes for the same level of inputs employed. They can also invent new products for which they can earn higher level of revenue by employing the same level of inputs (Aghion and Howitt, 1992; Grossman and Helpman, 1991) . However, heavy allocation of resources for R&D activity can also reduce efficiency if firms fail to reap the benefit of R&D (Helpman, 1992) .
It can also be hypothesized that large sized firms have natural advantages to do more of R&D related activities. This may arise if there is scale or scope effect in R&D intensity of the firms. Mazu conomies in the R&D activity of the Indian pharmaceutical firms. Additionally, large firms have greater market reach and more reputation, thus it is easier for large firms to market its new products successfully and earn higher returns. An interaction between the market share of firms and the R&D intensity is also considered to examine the joint effect of the size of the firms and its R&D efforts on its efficiency.
Increased participation in the international market is captured by the export earning of the firms and by their import of raw material and capital good. A number of studies have indicated that by exporting their products in the intern n higher efficiency (see Aw and Hang, 1995; Robert and Tybout, 1997; Clerides et al, 1998; World Bank Report, 1997) . There can be two sources of efficiency gains for firms selling their product in the international market. One is through 'learning by exporting' (see Clerides et al, 1998 , World Bank Report, 1993 ) and the other is by high prices for their products and hence higher value of output. However, to export in the international market a firm also has to invest heavily in resources to identify the foreign market and the potential customers through market research, building off shore marketing infrastructure, obtaining necessary legal documents etc (see Pradhan, 2009 ).
The return from such investment may not be immediate and firms may not get appropriate value for their products from their offshore investment if they fail to identify the potential markets 14 . Accordingly, the export earning of the firms per unit of its sales is included as an explanatory variable in our model to examine its impact on the efficiency of the firms 15 .
We also hypothesize that the large sized firms have some advantage to sell their products in the international market. Consequently, we have also considered the interaction between the export intensity and the market share of the firms to examine the joint ef fect the efficiency of the fect of the size of firms and its export earning on its efficiency.
Empirical evidence suggests that imported intermediary good is an important channel through which technological diffusion takes place (see, Tybout 2000) . This may favorably affect the production and hence the efficiency of the firms.
Generally, Indian pharmaceutical firms re-engineer the imported technology and learn about new designs, product and process 16 . Such activities enable firms to build up its internal production capabilities, competency and may positively af firms. Imported technology is measured as the ratio of firm's expenditure on imported capital good to its total value of sales. Since once imported technology, remains in the stock of the firm, the variable imported technology usages for the t th year is constructed by adding the figures for the imported technology from the base period to the t th period by taking 5 percent as the rate of depreciation.
Structural Variables
14 A number of studies have documented that because of various forms of entry barrier only the most productive firms self select for the global market.
The structure of a firm is largely determined by its size, technological parameters and product mix (Caves and Barton, 1990; Caves, 1992) . We take each of these factors re efficient because of the presence of threshold limit in production, scale e s and salaries and captures the degree of mechan ies which produce the basic raw-material and bulk and formula economic theory, the relationship between firm's age with its performance is again into consideration.
From the theoretical viewpoint the relationship between the size of firm and its efficiency is not clear (Audrestch, 1999) . On the one hand it can be hypothesized large size firms will be mo conomies and imperfection in capital market (Kumar, 2003) . However, beyond a certain level larger firm size may also plague a firm with X-inefficiency (Leibenstein, 1976) which may lead to lower efficiency. The output share of a firm in the total industry (Kwoka, 1978 ) is taken as a proxy for its size. To capture the possible non-linear effect between the output efficiency and the size of the firms we have also included the square of the output-share in the regression analysis.
Capital-labor ratio 17 is a technological variable considered in our regression model. It is measured by the ratio of company's expenses for plant-machinery, building, and other fixed asset to its expenditure for wage ization in the production process. We hypothesize that the degree of automation would increase efficiency.
With regard to product varieties three categories of firms are distinguished based on the product produced, viz., formulation companies which produce only the final product, bulk drug compan tion companies which produce both bulk and formulation products. Firms producing both bulk and formulation varieties are vertically integrated with raw-material industry and are expected to enjoy advantages of vertical integration (Coase, 1937; Hess, 1983; Williamson, 1981) compared to the other two categories. However, if there is internal co-ordination problem and control loss (Coase, 1937 , Williamson, 1967 firms may also lose efficiency. Firms are differentiated based on product produced with dummies, treating the formulation companies as the benchmark for our analysis.
We also control for the age of the firm in our analysis. From the point of ambiguous. Some authors suggest that older firms give superior performance since they are more experienced and enjoy the benefits of learning (Stinchcombe, 1965) . Others have however argued that older firms are prone to inertia and less flexible to changed economic circumstances (Marshall, 1920) . The age of a firm is calculated from the year of its incorporation.
Policy Related Variable
A time dummy has also been introduced taking value 1 from 1995 onwards and 0 for the rest of the year to examine the impact of policy reform on the efficiency of the firms. The year 1995 is chosen because the first version of product patent was . The Drug and Cosmetic Act was also amended in 1995 to infuse c implemented in that year ompetition for this sector. In other words important policy changes pertaining to this sector has taken place during this year.
The Model
Given the panel data, the OLS regression model is specified as
here j represents the jth firm j (=1, 2,…, N); subscript t denotes time (that spans from The independent variable in our model is jt x which is a vector of k factors that efficiency of the jth firms (=1-288) in the t-th time period an e t variables for our study are obtained from e Balance Sheets of the companies from the PROWESS database.
The exact specification of the fitted model was: The coefficient for the capital-labor ratio is negative and statistically significant which presently these capitals are not fully utilized is consistent with the low input-specific efficiency for capital reported in Table 1 . Contrary to the general perception, we find that with the rise in export intensity the efficiency of the firms falls 19 . Export markets for the generic products are of three types viz., the highly regulated generic market (such as market in USA, European
Most of the
Unions, Australia and so on), the semi-regulated generic market (such as Russi l and so) and the unregulated generic market (such as Sri-Lanka, Arab Emirates and so on). Generally, most of the firms target either the regulated or the unregulated market whereas a moderate proportion of the firms (almost 40 percent) also target the semi-regulated market. Exporting in the global regulated market for both the bulk drug and formulation is risky given the stringent regulatory norm that a firm has to follow to sell its product (Chaudhuri, 2005, pp 188-195) . If the value of output from such markets is not high enough to compensate for the expenditure incurred to comply with the regulatory barriers it leads to a fall in its efficiency ( as output efficiency is measured here 19 An interesting point to mention here is that a large number of pharmaceutical firms still sell their product in the domestic market. Though not reported we have differentiated the firms that sell their product in the domestic market from the firms that sell their product in the international using dummy variable. The result of our analysis confirms that firms targeting the international market are always better off.
in terms of value of output as against total expenditure on inputs). Although the regulated markets account for about 38.5% of India's total export and 50% of the bulk drug export in 2005, only a handful of Indian firms has benefited from the regulated market because of high cost of regulation 20 . In the unregulated market, there is no entry barrier, but the competition is intense and the value of output is less. On the other hand, in the semiregulated, the entry barrier is less compared to the regulated market and the benefit is more in comparison to the unregulated market. Few firms however target the semiregulated market and almost all the small sized firms target the unregulated market. We therefore find that efficiency falls with rise in export intensity.
However, the interaction between the size of the firms and its export intensity is significant with positive coefficient. This implies firms that are large and also exports more in the international market are better off. Generally, large sized firms have a better portfolio of products that they sell evenly across the regulated and semi-regulated markets. Thus, they can compensate for a loss of revenue in one market with the gain in another. In addition, large sized firms have better marketing network that also assist them to sell their product successfully.
Policy Related Variables
The coefficient of time dummy takes a negative value for the efficiency of the firms. This may happen due to two reasons. First, on an average the efficiency of the rms has deteriorated due to policy changes. Another possibility is that with petition it is plausible that the frontier has shifted fi liberalization and increased com outward due to entry of new efficient firms leading to a rise in the distance between frontier firms and the rest of the firms. Consequently, we find that there has been a fall in the average efficiency for the sector. The Malmquist analysis done by Majumdar and Rajeev (2008) shows that the sector has indeed experienced technological progress for a considerable period leading to an outward shift of the frontier and a fall in the efficiency of the firms. 
Conclusion
The present analysis attempts to examine the firm heterogeneity in the Indian Pharmaceutical industry by measuring their input and output efficiency. Based on our nalysis we can conclude that with policy changes the output efficiency of the Indian ector has declined. It appears that few large firms have been able to take the ben blic partnership in R&D. It is noticed that in the context a pharmaceutical s efit of a liberalized regime, but rest of the large number of small firms in the industry lagged behind. Further, analysis of the input and output efficiency reveals that even though firms have been able to use their inputs efficiently there has been a persistent decline in the output efficiency of the firms. We argue that such circumstance arises because of the 'economies of scale in production and the presence of large number of small firms that lie in the IRS zone of the empirically constructed production possibility set. Thus, one possible route to improve their efficiency will be to encourage merger to reap the benefit of economies of scale.
Our analysis also reveals the importance of firm specific characteristics to achieve higher efficiency. We find that increased investment in R&D will be a beneficial strategy for large sized firms. Thus, one possible way to encourage the firms to do more of R&D will be to involve in more of private-pu of the developed nation public support played a very important role to boost the R&D climate of the country see National Institute for Health Care Management Research and Educational Foundation (NICHM) (2000) . However, in India, public-private cooperation is currently not significant and it is necessary to improve such cooperation for the development of the industry (see also Chaudhuri, 2005) . Firms that are able to successfully market their product in the regulated market has to be technologically competent and this is seen through their efficiency scores as well. Small firms that cater mainly to the unregulated international or domestic market need to improve their efficiency to remain competitive in the long run and one way to do so is through merger.
In this context our study indicates that vertical merger is better than horizontal merger.
Therefore, firms producing only formulation or final product should merge with firms that produce the raw material or the bulk drug for the industry. Finally, the increased inefficiency levels depicted over time indicate that unless the inefficient firms 
